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In the present study, a novel series of 2-substituted benzimidazole derivatives were 
synthesized and characterized by means of IR, 1H-NMR, 13C- NMR, mass spectral and 
elemental analysis. The compounds were screened for antibacterial (Staphylococcus aureus 
ATCC9144, Staphylococcus epidermidis ATCC 155, klebsiella pneumoniae ATCC 29665 and 
Esherichia coli ATCC 25922) and antifungal (Candida albicans ATCC 2091 and Aspergillus 
niger ATCC 9029) activities. The Minimum Inhibitory Concentrations was determined by 
agar streak dilution method. 1-(4-(1H-benzo[d]imidazol-2-yl)phenyl)-3-chloro-4-(4-nitro 
phenyl)azetidin-2-one (3a) was found to exhibit the most potent in vitro antimicrobial 
activity with MIC of 15, 17, 19, 9, 11 and 15 µg/mL against E.coli, K.pneumoniae, S.aureus, 
S.epidermidis, C.albicans and A.niger respectively. All the other compounds exhibited 
moderate activity against the bacterial and fungal organism tested. 
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Benzimidazoles were reported to 
poses anticancer (Nare et al., 1994), 
antitubercular (Khyati et al., 2000, Jitendar et 
al., 2002), angiotensin-II receptor antagonists 
(Kohara et al., 1996) and antimicrobial 
properties (Davidet al., 2004). The 
azetidinone ring bearing compounds showed 
varied biological activities like antibacterial, 
antifungal and antitubercular activities and 
the thiazolidinone ring bearing compounds 
exhibited anticancer, antimicrobial, anti 
inflammatory & analgesic activities (Shiva et 
al 1981). The wide range of therapeutic value 
of these nucleuses promoted us to synthesize 
compounds comprised of the benzimidazole 
schiff base, thiazolidine and azetidinone ring 
system with substitution at 2nd position and 
also substitution with different electron 
withdrawing and electron donating groups 
which would poses potential antimicrobial 
properties. In the present study, a novel series 
of 2–substituted benzimidazole and its 
derivates were synthesized and characterized 
by IR, 1H-NMR, 13C-NMR, mass spectral and 
elemental analysis. The compounds were 
screened for antibacterial and antifungal 
activities. The minimum inhibitory 
concentrations (MIC) were also determined 
by agar streak dilution method. 
 
Materials and Methods 
Materials 
The melting points were taken in open 
capillary tube and are uncorrected. The IR 
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spectra of the compounds were recorded on 
ABB Bomen FTIR spectrometer MB 104 with 
KBr Pellets. 1H-NMR spectra were recorded 
on 300 MHz – Bruker DPX 200. The chemical 
shifts are reported as parts per million down 
field from tetramethylsilane. Mass spectra 
were recorded on Finnigan MAT 8230. Micro 
analyses for C, H, N were performed in 
Heraeus CHN repaid analyzer. All the 
compounds gave satisfactory chemical 
analyses (± 0.4%). The purity of the 
compounds were checked by TLC on 
precoated SiO2 gel (HF254 200 mesh) 
aluminium plates (E Merck). 
 
General Procedures. The synthetic strategy 
leading to the target compounds are 
illustrated in scheme 1. The thiazolidinone 
derivatives synthesized by equimolar 
quantities (0.01mol) of o-phenylenediamine, 
p-amino benzoic acid (0.01mol) in 4N HCl 
(20mL) was refluxed for 30 min. The mixture 
is cooled and filtered off. The residue is the 4-
(1H-benzo[d] imidazol-2-yl) benzenamine 1. 
The product is recrystallized from absolute 
alcohol. This compound was obtained as a 
pale yellow solid; Yield 89%; mp 209oC -
2110C. 
 
General method of synthesis of schiff bases 
(2a-2e) 
A mixture of equimolar quantities (0.01mol) 
of aromatic aldehyde and 4-(1H-benzo[d] 
imidazol-2-yl) benzenamine 1 was refluxed 
for 20 min in 20 mL of ethanol. The reaction 
mixture was cooled and kept for 24 h. The 
crystals found was filtered and dried. The 
schiff base N-(4-substituted benzylidine)-4-
(1H-benzo[d]imidazol-2-yl) benzenamine (2a-
2e) recrystallized from ethanol.  
 
General method of synthesis of 
azetidinones (3a-3e)  
A mixture of schiff base (0.001mol) and 
triethylamine (0.003mol) was dissolved in 1,4 
– Dioxan  (25mL), to this well stirred cooled 
solution of chloro acetyl  chloride (0.0012mol) 
was added drop wise at 10oC. The reaction 
mixture was stirred for 6 hours. Half of the 
solvent separated and yield 1-(4-(1H-
benzo[d]imidazol-2-yl) phenyl)-3-chloro-4-(4-
substituted phenyl) azetidin-2-one (3a-3e) 
recrystallized from chloroform. 
 
General method of synthesis of 
thiazolidinones (4a-4e) 
A mixture of schiff base (0.001mol) and 
thioglycollic acid (0.001mol) dissolved in 1,4 
dioxane (20mL), anhydrous zinc chloride 
(0.5mg) was added and refluxed for 8 h. The 
reaction was then cooled and the resulting 
solid was washed with sodium bicarbonate 
solution and final compound 3-(4-(1H-
benzo[d]imidazol-2-yl)phenyl)-2-(4-
substituted phenyl)thiazolidin-4-one (4a-4e) 
recrystallized from absolute ethanol. 
 
N-(4-nitro benzylidine)-4-(1H-benzo[d] 
imidazol-2-yl) benzenamine (2a) 
This compound was obtained as a yellow 
solid; Yield 91%; mp 265oC-267oC; IR (KBr) 
cm-1; 3048 (Ar-H), 3338 (N-H), 1423 (C-N), 
1601 (C=N), 1518, 1344 (Ar-NO2), 1H-NMR 
(CDCl3) δ: 7.2-8.2 (m, 12H Ar-H); 10.1 (1H, 
NH,) 8.39 (s, 1H, N-CH); 13C- NMR (CDCl3) δ: 
160.1 (N-CH), 152.9 (C-2), 150.7 (C-4" ), 139.7 ( 
C-1"), 138.4 (C-8 & C-9) 130.1 (C-2"), 129.0 (C-
1'), 128.5 (C-2'&C-6'), 123.2 (C-5&C-6), 122.7 
(C-3'), 121.0 (C-3"&C-5"), 120.8 (C-6"), 115.1 
(C-4& C-7) 153.2 (C-4'); EI-MS m/z (M+): 342 
(calcd for C20H14N4O2: 342.35).  Anal calcd for 
C20H14N4O2: C, 70.17; H, 4.12; N, 16.37, Found: 
C, 69.97; H, 4.13; N, 16.28. 
 
N-(4-chloro benzylidine)-4-(1H-benzo[d] 
imidazol-2-yl) benzenamine (2b) 
This compound was obtained as a pale 
yellow solid; Yield 78%; mp 215oC-217oC; IR 
(KBr)  cm-1; 2998 (Ar-H), 3358 (N-H), 1382 (C-
N), 1601 (C=N), 778 (Ar-Cl), 1H-NMR(CDCl3) 
δ : 7.0-8.1 (m, 12H, Ar-H), 9.9 (1H, NH,) 8.35 
(s, 1H, N-CH); 13C- NMR (CDCl3) δ : 160.1 (N-
CH),  153.1 (C-4'), 152.6 (C-2), 138.7 (C-8 & C-
9),  136.7 (C-4" ), 131.7 ( C-1"),  130.5 (C-2"& C-
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6"), 129.0 (C-3"&C-5"), 128.6 (C-2'&C-6'),  129.7 
( C-1"), 123.1 (C-5&C-6), 115.3 (C-4& C-7), 
122.7(C-3'); EI-MS m/z (M+): 332 (calcd for 
C20H14ClN3 : 331.79). Anal calcd for 
C20H14ClN3: C, 72.40; H, 4.25; N, 12.66, Found: 
C, 72.51; H, 4.22; N, 12.68. 
 
Scheme 1 
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N-(4-methoxybenzylidine)-4-(1H-
benzo[d]imidazol-2-yl) benzenamine (2c) 
This compound was obtained as a cream 
solid; Yield 78%; mp 210oC-212oC;  IR (KBr) 
cm-1; 3048 (Ar-H), 3366 (N-H), 1410 (C-N), 
1597 (C=N), 1202 (Ar-OCH3); 1H- NMR 
(CDCl3) δ :7.0-7.8 (m, 12H, Ar-H), 9.8 (1H, 
NH), 3.9 (3H, OCH3); 13C- NMR (CDCl3) δ : 
163.0 (C-4"), 160.1 (N-CH), 153.1 (C-4'),  152.7 
(C-2), 138.7 (C-8 & C-9), 130.2 (C-2"& C-6"), 
129.2 (C-1"), 128.8 (C-2'&C-6'), 126.1 (C-1"), 
123.0 (C-5&C-6), 122.8 (C-3'), 115.3 (C-4& C-
7), 114.4 (C-3"&C-5"), 55.9 (C-7");  EI-MS m/z 
(M+): 327 (calcd for  C21H17ClN3O: 327.37). 
Anal calcd for C21H17ClN3O: C, 77.04; H, 5.23; 
N, 12.84, Found: C, 77.19; H, 5.21; N, 12.81. 
 
4-(4-(1H-benzo[d]imidazolo-2-yl) 
phenylimino) methyl-2-methoxy phenol (2d) 
This compound was obtained as a brown 
crystals; Yield 72%; mp 260oC-262oC;  IR 
(KBr) cm-1; 3124 (Ar-H), 1408 (N-H), 1603 (C-
N), 1221 (C=N), 1201 (Ar-OCH3), 3319 (Ar-
OH); 1H- NMR (CDCl3) δ: 6.6-7.8 (m, 12H, Ar-
H), 9.8 (1H, NH), 8.1 (s, 1H, N-CH), 3.9 (3H, 
Ar-OCH3), 11.9 (1H   Ar-OH); 13C- NMR 
(CDCl3) δ: 160.1 (N-CH), 153.2 (C-4'), 152.9 
(C-2), 151.5 (C-3"), 148.0 (C-4"), 138.9 (C-8&C-
9), 129.2 (C-1'), 128.8 (C-2'&C-6'), 127.4 (C-1"), 
123.0 (C-5&C-6), 122.8 (C-3'& C-5'), 117.0 (C-
5"), 115.3 (C-4&C-7), 56.2 (C-3"); EI-MS m/z 
(M+): 342 (calcd for C21H17N3O2 : 343.37).  Anal 
calcd for C21H17N3O2: C, 73.45; H, 4.99; N, 
12.24, Found: C, 73.29; H, 4.96; N, 12.17. 
 
N-(4-methyl benzylidine)-4-(1H-benzo[d] 
imidazol-2-yl) benzenamine (2e) 
This compound was obtained as a white 
solid; Yield 60%; mp 230oC-232oC; IR (KBr) 
cm-1; 3028 (Ar-H), 3376 (N-H), 1422 (C-N), 
1594 (C=N), 2918, 2859 (Ar-CH3), 1H-NMR 
(CDCl3) δ: 7.1-7.9 (m, 12H, Ar-H), 9.9 (1H, 
NH), CH3 (3H, CH3), 8.4 (s, 1H, N-CH); 13C- 
NMR (CDCl3) δ: 160.1 (N-CH), 153.2 (C-4'), 
152.1 (C-2), 140.7 (C-4"), 138.9 (C-8&C-9), 
130.8 (C-1"), 129.2(C-1', C-5'& C-3"), 128.8 (C-
2’&C-6'), 129.2 (C-2"& C-5"), 123.0 (C-5&C-6) 
122.8 (C-3'), 115.3 (C-4&C-7), 24.3 (C-7"); EI-
MS m/z (M+): 311 (calcd for C21H17N3: 
311.37). Anal calcd for C21H17N3: C, 81.00; H, 
5.50; N, 13.49, Found: C, 81.09; H, 5.57; N, 
13.38. 
 
1-(4-(1H-benzo[d]imidazol-2-yl) phenyl)-3-
chloro-4-(4-nitrophenyl)azetidin-2-one (3a) 
This compound was obtained as a pale brown 
solid; Yield 76%; mp 234oC-236oC; IR (KBr) 
Cm-1; 2975 (Ar-H), 3200 (N-H), 1398 (C-N), 
1601 (C=N), 1518, 1344 (Ar-NO2), 812 (CH-Cl) 
1686 (β-Lactam, C=O); 1H-NMR (CDCl3) δ: 
7.3-8.7 (m, 12H, Ar-H), 10.1 (s, 1H, NH), 3.1 
(d, 1H, aze.CH); 13C- NMR (CDCl3) δ: 162.1 
(C-9"), 152.1 (C-2), 149.8 (C-1"), 148.4 (C-4"), 
141.7 (C-4'), 138.9 (C-8&C-9), 127.9 (C-2"& C-
6"), 127.7 (C-2 '& C-6'), 123.0 (C-5&C-6), 122.1 
(C-3'&C-5'), 120.9 (C-3"&C-5"), 115.3 (C-4&C-
7), 126.3 (C-1'), 63.1(C-7"), 62.0 (C-8"); EI-MS 
m/z (M+): 418 (calcd for C22H15ClN4O3: 418). 
Anal calcd for C22H15ClN4O3: C, 60.09; H, 3.61; 
N, 13.38, Found: C, 63.01; H, 3.67; N, 13.41.      
 
1-(4-(1H-benzo[d]imidazol-2-yl)phenyl)-3-
chloro-4-(4-chlorophenyl)azetidin-2-one (3b) 
This compound was obtained as a pale 
yellow solid; Yield 48%; mp 228oC-230oC; IR 
(KBr) cm-1; 3073 (Ar-H), 3264 (NH), 1406 (C-
N), 1599 (C=N), 826 (Ar-Cl), 772 (CH-Cl) 
1681(β-Lactam C=O); 1H- NMR (CDCl3) δ: 
7.0-8.4 (m, 12H, Ar-H), 9.9 (s, 1H,  NH), 3.3 (d, 
1H, aze.CH);  13C- NMR (CDCl3) δ: 162.2 (C-
9"), 152.9 (C-2), 141.7 (C-4'), 141.6 (C-1"), 138.9 
(C-8&C-9), 132.3 (C-4"), 128.7 (C-3"&C-5"), 
128.4 (C-2"&C-6"), 127.7 (C-2'&C-6'), 126.3( C-
1'), 123.0 (C-5&C-6), 122.1 (C-3'&C-5'), 115.3 
(C-4&C-7), 63.1 (C-7"), 62.0 (C-8"); EI-MS m/z 
(M+): 408 (calcd for C22H15Cl2N3O: 408.28) 
Anal calcd for C22H15Cl2N3O: C, 64.72; H, 3.70; 
N, 10.29, Found: C, 64.77; H, 3.67; N, 10.26.   
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1-(4-(1H-benzo[d]imidazol-2-yl)phenyl)-3-
chloro-4-(4-methoxyphenyl)azetidin-2-one 
(3c) 
This compound was obtained as a yellow 
solid; Yield 72%; mp 210oC-212oC; IR (KBr) 
cm-1; 3022 (Ar-H), 3337 (NH), 1407 (C-N), 
1605 (C=N), 1247 (Ar- OCH3), 799 (CH-Cl) 
1681 (β-Lactam C=O); 1H- NMR (CDCl3) δ: 
7.0-7.8 (m, 12H, Ar-H), 9.8 (s, 1H, NH), 3.9 (d, 
1H, aze.CH); 13C- NMR (CDCl3) δ: 162.2 (C-
9"), 158.7 (C-4"), 152.1 (C-2), 141.7 (C-4'), 138.9 
( C-8&C-9), 135.8 (C-1"), 128.0 (C-2"&C-6"), 
127.7 (C-2'&C-6'), 123.0 (C-5&C-6), 126.3 (C-
1'), 122.1 ( C-3'&C-5'), 115.3 (C-4&C-7), 114.4 
(C-5"), 63.1 (C-7"), 62.0 (C-8" ), 55.9 (C-10"); EI-
MS m/z (M+): 403 (calcd for C23H18ClN3O2 : 
403.86). Anal calcd for C23H18ClN3O2: C, 68.40; 
H, 4.49; N, 10.40, Found: C, 68.37; H, 4.51; N, 
10.36. 
 
1-(4-(1H-benzo[d]imidazol-2-yl)phenyl)-3-
chloro-4-(4-hydroxy-3-methoxyphenyl)           
azetidin-2-one (3d) 
This compound was obtained as a yellow 
solid; Yield 76%; mp 220oC-222oC; IR (KBr) 
cm-1; 3001 (Ar-H), 3227 (NH), 1406 (C-N), 
1593 (C=N), 1246 (Ar-OCH3), 795 (CHCl) 1675 
(β-Lactam C=O); 1H-NMR (CDCl3) δ: 6.6.-7.8 
(m, 12H, Ar-H), 9.8(s, 1H, NH), 3.1 (d, 1H, 
aze.CH); 13C- NMR (CDCl3) δ:  162.2 (C-9"), 
152.9 (C-2), 151.2 (C-3"), 143.7 (C-4"), 141.7 (C-
4'), 138.9 (C-8&C-9), 137.1 (C-1"), 127.7 (C-
2'&C-6'), 126.3 (C-1'), 123.0 (C-5&C-6), 122.1 
(C-3'&C-5'), 120.7 (C-6"), 116.7 (C-5"), 115.3 
(C-7&C-4),  112.4 (C-2"), 63.4 (C-7"), 62.0 (C-
8"), 56.2 (C-10"); EI-MS m/z (M+): 419 (calcd 
for C23H18ClN3O3: 419.86). Anal calcd for 
C23H18ClN3O3: C, 65.79; H, 4.32; N, 10.01, 
Found: C, 65.81; H, 4.29; N, 10.08.  
 
1-(4-(1H-benzo[d]imidazol-2-yl)phenyl)-3-
chloro-4-p-tolyl azetidin-2-one (3e) 
This compound was obtained as a pale brown 
solid; Yield 32%; mp 130oC-132oC; IR (KBr) 
cm-1; 3028 (Ar-H), 3376 (NH), 1411 (C-N),  
1603 (C=N), 2918, 2859 (Ar-CH3), 817 (Ar-Cl), 
1678 (β-Lactam C=O); 1H- NMR (CDCl3) δ: 
7.1-7.8 (m, 12H, Ar-H), 9.9 (s, 1H, NH), 2.4 
(3H, CH3), 3.1 (d, 1H, Ar-H), 13C- NMR δ: 
162.2 (C-9"), 152.9 (C-2), 141.7 (C-4'), 140.5 (C-
1"), 138.9 (C-8&C-9), 136.4 (C-4"), 128.9 (C-
5"&C-3"), 127.7 (C-2'&C-6'), 126.9 (C-2"&C-6"), 
126.3 (C-1'), 123.0 (C-5&C-6), 122.1 (C-5'&C-
3'), 115.3 (C-4&C-7), 63.1 (C-7"), 62.0 (C-8"), 
24.3 (C-10"); EI-MS m/z (M+): 387 (calcd for 
C23H18ClN3O: 387.86). Anal calcd for 
C23H18ClN3O: C, 71.22; H, 4.68; N, 10.83, 
Found: C, 71.33; H, 4.65; N, 10.79.  
 
3-(4-(1H-benzo[d]imidazol-2-yl)phenyl)-2-
(4-nitro phenyl)thiazolidin-4-one (4a)  
This compound was obtained as a white 
crystals; Yield 36%;  mp 256oC-258oC;  IR 
(KBr) cm-1; 3077 (Ar-H), 3340 (NH), 1417 (C-
N) 1598 (C=N), 1515, 1343 (Ar-NO2), 1701 
(C=O), 1105 (C-S); 1H- NMR (CDCl3) δ: 7.1-8.0 
(m, 12H, Ar-H), 9.4 (s, 1H, NH), 3.5 (2H, 
thiazolidinone CH2), 3.9 (1H, thiazolidinone 
CH); 13C- NMR δ: 171.2 (C-4"'), 152.9 (C-2), 
146.8 (C-4), 145.3 (C-1"), 141.3 (C-4'), 138.9 (C-
8&C-9), 129.7 (C-2"&C-6"), 127.7 (C-2'&C-6'), 
126.8 (C-1'), 123.0 (C-5&C-6), 122.2 (C-5'&C-
3'), 121.0 (C-3"&C-5"), 115.3 (C-4&C-7), 65.6 
(C-1"'), 33.6 (C-5"'). EI-MS m/z (M+): 416 
(calcd for C22H16N4O3S: 416.18). Anal calcd for 
C22H16N4O3S: C, 63.45; H, 3.87; N, 13.45, 
Found: C, 63.37; H, 3.91; N, 13.51. 
 
3-(4-(1H-benzo[d]imidazol-2-yl)phenyl)-2-
(4-chloro phenyl)thiazolidin-4-one (4b) 
This compound was obtained as a brown 
solid; Yield 22%; mp 208oC-210oC; IR (KBr) 
cm-1; 3350 (NH), 1403 (C-N), 1590 (C=N), 783 
(Ar-Cl), 1693 (C=O), 1118 (C-S); 1H-NMR 
(CDCl3) δ: 7.1-7.7(m, 12H, Ar-H), 8.9 (s, 1H, 
NH), 3.9 (2H– thiazolidinone CH2), 3.7 (1H, 
thiazolidinone CH) 13C- NMR (CDCl3) δ : 
171.2 (C-4"'), 152 (C-2), 141.7 (C-4'), 138.9 (C-
8&C-9), 137.3 (C-1"), 130.2 (C-2"&C-6"), 128.8 
(C-3"&C-5"), 127.7 (C-2'&C-6'), 126.3 (C-1'), 
123.0 (C-5&C-6), 122.1 (C-3 '&C-5'), 115.3 (C-
4&C-7), 65.6 (C-2"'), 33.6 (C-5"'); EI-MS m/z 
(M+): 405 (calcd for C22H16ClN3OS: 405.89). 
Anal calcd for C22H16ClN3OS: C, 65.10; H, 
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3.97; N, 10.35, Found: C, 65.13; H, 4.03; N, 
10.41. 
 
3-(4-(1H-benzo[d]imidazol-2-yl)phenyl)-2-
(4-methoxy phenyl)thiazolidin-4-one (4c) 
This compound was obtained as a pale 
yellow solid; Yield 30%; mp-190oC-192oC;  IR 
(KBr) cm-1; 3011 (Ar-H) 3198 (NH), 1420 (C-N) 
1602 (C=N), 1214 (Ar-OCH3), 1684 (C=O), 
1109 (C-S); 1H- NMR (CDCl3) δ: 6.6-7.9 (m, 
12H, Ar-H), 8.7 (s, 1H, NH), 3.36 (3H,OCH3), 
3.81 (2H, thiazolidinone CH2), 5.9 (1H, 
thiazolidinone CH), 13C- NMR (CDCl3) δ: 
171.2 (C-4"'), 159.1 (C-4"), 152 (C-2), 141.7 (C-
4'), 138.9 (C-8&C-9), 131.5 (C-1"), 129.8 (C-
2"&C-6"), 127.7 (C-2'&C-6'), 126.3 (C-1'), 123.0 
(C-5&C-6), 122.1 (C-3'&C-5'), 115.3 (C-4&C-7), 
114.2 (C-3"&C-5") ,65.6 (C-2"'), 55.9 (C-7"), 
33.6 (C-5"'); EI-MS m/z (M+): 401 (calcd for 
C23H19N3O2S: 401.48). Anal calcd for 
C23H19N3O2S: C, 68.81; H, 4.77; N, 10.47, 
Found: C, 68.79; H, 4.80; N, 10.44. 
 
3-(4-(1H-benzo[d]imidazol-2-yl)phenyl)-2-
(4-hydroxy-3-(methoxyphenyl)thiazolidine-
4-one (4d) 
This compound was obtained as a pale brown 
solid; Yield 46%; mp 290oC-292oC;   IR (KBr) 
cm-1; 3033 (Ar-H), 3124 (NH), 1394 (C-N), 
1604 (C-N), 1208 (Ar-OCH3), 3356 (Ar-OH), 
719 (C=O), 1108 (C-S); 1H- NMR (CDCl3) δ: 
6.5-7.8 (m, 12H, Ar-H), 8.6 (s, 1H,NH), 3.46 
(3H, OCH3), 11.6 (1H, ArOH), 4.4 (2H, 
thiazolidinone CH2), 3.56 (1H, thiazolidinone 
CH); 13C- NMR (CDCl3) δ:  171.2 (C-4"'), 152 
(C-2), 151.3 (C-3") 144.1 (C-4"), 141.7 (C-4'), 
138.9 (C-8&C-9), 132.8 (C-1"), 127.7 (C-2'&C-
6'), 126.3 (C-1), 122.5 (C-2"), 122.1 (C-3&C-5'), 
23.6 (C-5&C-6), 116.8 (C-5"), 115.3 (C-4&C-7), 
114.2 (C-2"), 65.9 (C-2"'), 56.2 (C-7"), 33.6 (C-
5"'); EI-MS m/z (M+) 417  (calcd for 
C23H19N3O3S: 417.48). Anal calcd for 
C23H19N3O3S: C, 66.17; H, 4.59; N, 10.07, 
Found: C, 66.13; H, 4.61; N, 10.01. 
 
3-(4-(1H-benzo[d]imidazol-2-yl)phenyl)-2-p-
tolylthiazolidin-4-one (4e) 
This compound was obtained as a white 
crystals; Yield 24%; mp 235oC-237oC; IR (KBr) 
cm-1; 3023 (Ar-H), 3359 (NH), 1393 (C-N) 1604 
(C=N), 2919, 2857 (Ar-CH3), 1700 (C=O), 1117 
(C-S); 1H-NMR (CDCl3) δ: 7.0-8.0 (m, 12H, Ar-
H), 10.3 (s, 1H, NH), 2.6 (3H,CH3), 3.9 (2H, 
thiazolidinone CH2), 3.5 (1H, Thiazolidinone 
CH), 13C- NMR (CDCl3) δ: 171.2 (C-4"'), 152 
(C-2), 141.7 (C-4') 138.9 (C-8&C-9), 136.8 (C-
4"), 136.2 (C-1"), 129.0 (C-3"&C-5"), 128.7 (C-
2"&C-6"), 127.7 (C-2'&C-6'), 126.3 (C-1'), 123.0 
(C-5&C-6), 122.1 (C-3'&C-5'), 115.3 (C-4&C-7), 
65.6 (C-2"'), 33.6 (C-5"'), 24.3 (C-7"); EI-MS 
m/z (M+): 385 (calcd for C23H19N3OS:385.48). 
Anal calcd for C23H19N3OS: C71.66; H, 4.97; N, 
10.90, Found: C, 71.58; H, 4.92; N, 10.81. 
 
Antimicrobial Screening 
The in vitro antibacterial (Staphylococcus 
aureus ATCC9144, Staphylococuss epidermidis 
ATCC 155, Klebsiella pneumoniae ATCC 29665 
and Escherichia coli ATCC 25922) and 
antifungal (Candida albicans ATCC 2091 and 
Aspergillus niger ATCC 9029) activities of the 
compounds were evaluated by paper disc 
diffusion method. The minimum inhibitory 
concentrations of the compounds were also 
determined by agar streak dilution method. 
 
Paper disc diffusion method 
The sterilized (Gilles, 1994) (autoclaved at 
120oC for 30 min) medium (40-50oC) was 
inoculated (1mL/100mL of medium) with the 
suspension (105 cfu/mL) of the micro 
organism (matched to McFarland barium 
sulphate standard) and poured into a 
petridish to give a depth of 3-4 mm. The 
paper impregnated with the test compounds 
(25, 50, 100  µg/mL in dimethyl formamide) 
was placed on the solidified medium. The 
plates were preincubated for 1h at room 
temperature and incubated at 37oC for 24 h 
and 48h for anti bacterial and antifungal 
activity respectively. Ciprofloxacin (Dr. 
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Reddy’s Laboratories, Batch no. IC 666 Eo4 
India) and ketoconazole (Wuhan Shengmao 
Corporation Batch no: SBML/403, China) was 
used as standard for antibacterial and anti 
fungal activity respectively. The observed 
zone of inhibition is presented in Table 1. 
  
Minimum Inhibitory concentration 
Minimum inhibitory concentration 
(Hawkey,1994) (MIC) of the test compounds 
were determined by agar streak dilution 
method. A stock solution of the synthesized 
compound [50 µg/mL] in dimethyl-
formamide was prepared and graded 
quantities of the test compounds were 
incorporated in specified quantity of molten 
sterile agar (nutrient agar for antibacterial 
activity and sabouraud dextrose agar 
medium for anti fungal activity) A specified 
quantity of the medium (40-50oC) containing 
the compound was poured into a petridish to 
give a depth of 3-4mm and allowed to 
solidify suspension of the microorganism 
were prepared to contain approximately 105 
Cfu/mL and applied to plates with serially 
diluted compounds in dimethylformamide to 
be tested and incubated at 37oC for 14h and 
48h for bacteria and fungi  respectively. The 
MIC was considered to be lowest 
concentration of the test substance exhibiting 
no visible great of bacteria or fungi, on the 
plate. The observed MIC is presented in Table 
1. 
 
 
Table 1 Antimicrobial activity of the synthesized compounds 
Compound 
In vitro activity – Zone of inhibition (MIC) 
E. coli K. pneumoniae S. aureus S. epidermidis C. albicans A. niger 
2a 22(19) 16(21) 16(21) 30(9) 22(14) 15(16) 
2b 25(14) 15(19) 12(31) 25(14) 17(18) 13(21) 
2c 20(23) 13(27) 15(22) 23(19) 15(23) 9 (26) 
2d 21(17) 15(22) 14(26) 28(12) 24(10) 12(19) 
2e 13(30) 13(31) 12(31) 18(22) 18(20) 10(32) 
3a 28(15) 20(17) 17(19) 25(9) 24(11) 14(15) 
3b 14(31) 26(12) 13(27) 25(12) 21(15) 12(20) 
3c 17(21) 14(26) 18(16) 21(18) 20(18) 9(31) 
3d 19(19) 18(20) 12(32) 23(14) 18(21) 11(24) 
3e 15(12) 10(29) 13(25) 17(24) 15(26) 9(28) 
4a 23(16) 16(19) 15(22) 26(13) 24(9) 13(19) 
4b 25(12) 15(24) 19(13) 16(21) 22(13) 12(23) 
4c 21(19) 12(29) 13(28) 14(24) 20(19) 15(12) 
4d 25(9) 15(22) 16(19) 18(20) 24(11) 8(32) 
4e 20(21) 14(24) 11(32) 15(26) 11(25) 12(26) 
Ciprofloxacin 29 27 25 34 - - 
Zone of inhibition in mm, MIC in µg/mL 
 
Results and Discussion 
All the synthesized compounds exhibited 
significant antibacterial and moderate to 
potent antifungal activity. 2-substituted 
benzimidazole schiff bases and its 
azetidinone and thiazolidinone derivatives 
were found to exhibit most potent 
antimicrobial activity against all the microbial 
stains tested. All the compounds were active 
against all tested micro organism with a 
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range of MIC values for S. aureus (13-32 
µg/mL), S. epidermidis (9-26 µg/mL), K. 
pneumoniae (12-31 µg/mL), E.coli (9-
31µg/mL), C.albicans (9-25 µg/mL) and 
A.niger (12-32 µg/mL). Compounds 2a, 4a 
and 4d exhibited potent antimicrobial activity 
(MIC: 9 µg/mL) against S. epidermidis (E-coli 
and C. albicans compounds 3b and 4c showed 
significant activity (12 µg/mL) against K. 
pneumoniae and A. niger).  Compounds 3e and 
4b were found to be active (MIC: 12 µg/mL) 
against E. coli. Compounds 2d and 3a 
exhibited significant activity against S. 
epidermidis (MIC: 12 µg/mL) and C. albicans 
(MIC: 11 µg/mL) respectively. Compounds 
2b, 2c, 2e, 3c, 3d and 4e were found to exhibit 
moderate to potent antimicrobial properties.  
The data revealed that electron withdrawing 
groups like -NO2, -Cl, and electron donating 
group like -OCH3, -OH were found to 
increase the antimicrobial properties, whereas 
electron donating group like -CH3 group 
found to have moderate activity. The most of 
the synthesized compounds exhibited 
significant antibacterial activity and moderate 
antifungal activity. 
 
Structure-activity relationship  studies 
Structure-activity relationship (SAR) studies 
revealed that different substitutions on the 
benzimidazole schiff bases and its 
azetidinone and thiazolidinone derivatives 
exerted varied biological activity. The 
electronic nature of the substituent groups at 
4' positions in benzimidazole nucleus, 7'' 
azetidinone and 2''' thiazolidinone led to 
significant variation in antimicrobial activity. 
Among the series compounds substituted by 
electron-withdrawing (-NO2 and -Cl) and 
electron-donating (-OCH3, -OH and -CH3) 
groups are enhanced biological activity. 
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